Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer

Purpose. The aim of this study was to assess the safety and tolerability of motesanib (an orally administered small-molecule antagonist of vascular endothelial growth factor receptors 1, 2, and 3, platelet-derived growth factor receptor, and Kit) when administered in combination with panitumumab, ge...

Descripción completa

Detalles Bibliográficos
Autores principales: Burris, Howard, Stephenson, Joe, Otterson, Gregory A., Stein, Mark, McGreivy, Jesse, Sun, Yu-Nien, Ingram, Megan, Ye, Yining, Schwartzberg, Lee S.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087488/
https://www.ncbi.nlm.nih.gov/pubmed/21559248
http://dx.doi.org/10.1155/2011/853931

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3087488/
https://www.ncbi.nlm.nih.gov/pubmed/21559248
http://dx.doi.org/10.1155/2011/853931

Ejemplares similares